REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

1. A class action lawsuit filed against Regeneron for alleged securities law violations. 2. Case claims misrepresentation of discounts affected financial disclosures. 3. Investors affected between November 2023 and October 2024 are encouraged to join. 4. No upfront costs for investors; payment contingent on case success. 5. Bronstein, Gewirtz & Grossman is a recognized firm in securities class actions.

Legal

75

4m saved

Insight

Article

FAQ

Why Bearish?

Lawsuits can negatively affect stock prices, like in past cases with similar allegations.

How important is it?

The lawsuit directly impacts investor perception and share price; historical precedents support this.

Why Short Term?

Legal issues may impact stock performance until resolved or clarified.

Related Companies

REGN

NEW YORK, Jan. 12, 2025 /PRNewswire/ -- Attorney Advertising --

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/REGN.

Case Details

The Complaint alleges that throughout the Class Period, Defendants made misrepresentations regarding potential violations of the False Claims Act by failing to report millions of dollars in discounts provided to drug distributors in the form of reimbursed credit card fees.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/REGN. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Regeneron you have until March 10, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC